All In Biotech

Drug Trial Radar · NCT05537987

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

A Multicenter, Open-Label Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 30, 2021

Primary completion

Nov 2023

Study completion Jul 2024

Sponsor

Lead sponsor
InnoCare Pharma Inc.Industry
Sponsor type
Industry
First posted
Sep 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

During this study, dose escalation will be conducted in subjects with advanced solid tumors who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, tolerability, and PK of ICP-723

Conditions

  • Advanced Solid Tumors

Interventions

  • ICP-723Drug

    3+3 dose escalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensityTime frame: through study completion, an average of 1.5 years.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Medical / Cancer Centers

    Kansas City, Kansas

  • NYU-Langone Medical Center

    New York, New York

  • Northwest Medical Specialties

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.